Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis

Article, Other literature type English OPEN
Westwood, M.; Joore, M.; Whiting, P.; van Asselt, T.; Ramaekers, B.; Armstrong, N.; Misso, K.; Severens, J.; Kleijnen, J.;
(2014)
  • Publisher: NIHR Journals Library
  • Journal: Health Technology Assessment (issn: 2046-4924)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.3310/hta18320, pmc: PMC4781337
  • Subject: Research Article | CHINESE PATIENTS PTS | INDIVIDUAL PATIENT DATA | CLINICALLY SELECTED PATIENTS | RANDOMIZED PHASE-III | PLUS GEMCITABINE GEM | Medical technology | GEFITINIB STUDY-GROUP | GROUP TRIAL WJTOG0403 | R855-855.5 | PERFORMANCE LIQUID-CHROMATOGRAPHY | CHEMOTHERAPY-NAIVE PATIENTS | NSCLC PATIENTS PTS

BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. Some epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutations make tumours responsive to treatment with EGFR-TK inhibitors (EGFR-TKIs) but less responsive to treatment wit... View more
Share - Bookmark